Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PCSK9 inhibitor in anti-rejection after cardiac transplantation

A technology for heart transplantation and rejection, applied in the medical field, can solve problems such as infection, no anti-rejection treatment, neurotoxicity, etc., and achieve the effect of prolonging the survival period, reducing graft rejection, and prolonging survival time

Inactive Publication Date: 2021-09-03
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] But the drug isn't used in anti-rejection treatments after heart transplants
At the same time, the immunosuppressive regimens routinely used in clinical practice at this stage have limited effects on suppressing rejection after heart transplantation, and there are many side effects such as infection, tumor and neurotoxicity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PCSK9 inhibitor in anti-rejection after cardiac transplantation
  • Application of PCSK9 inhibitor in anti-rejection after cardiac transplantation
  • Application of PCSK9 inhibitor in anti-rejection after cardiac transplantation

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0032] Step 1, select sample mice, the number is forty. Among them, 20 donor mice (BALB / c) and 20 recipient mice (C57BL / 6);

[0033] Step 2. Select ten recipient mice to establish a heart transplant animal model, and detect the expression of PCSK9 in the transplanted heart and spleen seven days after the transplantation;

[0034] Step 3. Establish a heart transplantation model in another ten recipient mice, and the recipient mice receive ariroclizumab injection 24 hours before the operation, and observe the beating state of the transplanted heart of the mice after transplantation;

[0035] Step 4: From the first day after the transplantation, the mice were continued to be injected with arilocumab, and the beating state of the transplanted heart of the mice was observed daily thereafter. The complete cessation of beating of the transplanted heart was the end of the experiment, and the survival time of the graft was recorded;

[0036] in:

[0037] The dose of arirocurumab inj...

experiment example 2

[0041] The use of immunosuppressants alone in anti-rejection after heart transplantation:

[0042] Step 1, the selected immunosuppressant, preferably FK506;

[0043] Step 2, select sample mice, the number is 20. Among them, ten donor mice (BALB / c) and ten recipient mice (C57BL / 6);

[0044] Step 3. Establish a heart transplant model in ten recipient mice, and observe the beating state of the transplanted heart of the mice after transplantation;

[0045] Step 4: Intraperitoneal injection of FK506 was performed on the first day after transplantation, and the beating state of the transplanted heart of mice was observed daily thereafter. The complete cessation of beating of the transplanted heart was the end of the experiment, and the survival time of the graft was recorded;

[0046] in:

[0047] The dosage of FK506 is 1mg / kg / day, the mass of the injected body is 25-30mg, and the injection method of FK506 is intraperitoneal injection;

[0048] Step 5, on the 7th day and the 14...

experiment example 3

[0051] Combination of PCSK9 inhibitor and FK506 in anti-rejection after heart transplantation:

[0052] Step 1. The selected PCSK9 inhibitor is preferably arirocurumab, and the immunosuppressant is selected, preferably FK506;

[0053] Step 2, select sample mice, the number is 20. Among them, ten donor mice (BALB / c) and ten recipient mice (C57BL / 6);

[0054] Step 3. Ten recipient mice were established as heart transplantation models, and 24 small recipient mice were injected with arirocurumab before surgery, and the beating state of the transplanted hearts of the mice was observed after transplantation;

[0055] Step 4: From the first day after the transplantation, the mice were injected with arirociumab and FK506, and the beating state of the transplanted heart of the mice was observed daily thereafter. The complete cessation of beating of the transplanted heart was the end of the experiment, and the survival time of the graft was recorded;

[0056] in:

[0057] The dose o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a PCSK9 inhibitor in anti-rejection after cardiac transplantation. The PCSK9 inhibitor is alirocumab, a usage mode of the PCSK9 inhibitor is of subcutaneous injection, and the dosage of use is 10mg / kg / week. According to the application of the PCSK9 inhibitor in the anti-rejection after the cardiac transplantation, provided by the invention, compared with that a rejection after cardiac transplantation is treated by purely using an immunosuppressant at present, after combined application of the PCSK9 inhibitor, the alleviation of an immunologic rejection after cardiac transplantation and the prolonging of survival time of a heart transplant are better facilitated. Furthermore, the survival cycle of the transplant can also be effectively prolonged by independently using the PCSK9 inhibitor.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of a PCSK9 inhibitor in anti-rejection after heart transplantation. Background technique [0002] A heart transplant is the surgical replacement of the failing heart of a patient with end-stage heart disease with a healthy donor heart from a brain-dead donor. The most difficult complication after transplantation is the rejection of the transplanted heart. The clinical symptoms include cardiac insufficiency, palpitations and asthma, low-grade fever, arrhythmia, edema of both lower limbs, facial swelling, pericardial effusion, and pleural effusion. , cough and shock, etc., are often life-threatening in severe cases, seriously affecting the long-term survival rate of patients after transplantation. Therefore, it is particularly important to formulate an effective treatment plan for postoperative rejection to improve the long-term survival rate of patients after tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K31/436A61P37/06
CPCC07K16/40A61K39/3955A61K31/436A61P37/06A61K2039/505A61K2300/00
Inventor 张曦夏家红吴杰于济彰邹艳强许恒陈漳李媛
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com